Amgen’s (AMGN) treatment of systemic sclerosis, blinatumomab, was granted FDA orphan designation, according to a post to the agency’s site.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- What’s Included in AstraZeneca’s (AZN) ‘Historic’ Drug Discount Deal with Trump?
- AstraZeneca Stock (AZN) Flat despite Incoming Trump Pricing Deal, Virginia Plant Construction
- Trump Weekly: Generics to be excluded from pharma tariff plan
- GoodRx Stock (GDRX) Pops as U.S. Pharmacies Unite to Lobby for TrumpRx Participation
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports